Measure:

Comprehensive Diabetes Care (CDC): Hemoglobin A1c (HbA1c) testing

DSRIP #:
29

Measure Description:
The percentage of patients 18-75 years of age with diabetes (Type 1 and Type 2) who had: Hemoglobin A1c (HbA1c) testing

Data Source:
MMIS

NQF #:
0057

Measure Steward:
NCQA

Measure Steward Version:
2013

Measure Calculation Description

Numerator:
An HbA1c test performed during the measurement year. (Table 29.1)

Table 29.1: Codes to Identify HbA1c Tests

Description	CPT
HbA1c Tests	83036, 83037

Denominator:

Of the hospital's New Jersey Low Income population, those patients aged 18-75 years of age as of December 31 of the measurement year who had a diagnosis of diabetes (type 1 or type 2).

Two methods are provided to identify patients with diabetes during the measurement year, or the year prior to the measurement year.
1. Pharmacy data – Patients who were dispensed insulin or oral hypoglycemic/ antihyperglycemics during the measurement year or the year prior to the measurement year. (Table 29.2) (Refer to Appendix A-15 for NDC codes)

Table 29.2: Prescriptions to Identify Patients With Diabetes

Description	Prescription		
Alpha-glucosidase inhibitors	• Acarbose	• Miglitol	
Amylin analogs	• Pramlinitide		
Antidiabetic combinations	• Glimepiride-pioglitazone • Glimepiride-rosiglitazone • Glipizide-metformin	• Glyburide-metformin • Metformin-pioglitazone • Metformin-rosiglitazone	• Metformin-sitagliptin • Saxagliptin • Sitagliptin-simvastatin
Insulin	• Insulin aspart • Insulin aspart-insulin aspart protamine • Insulin detemir • Insulin glargine	• Insulin isophane human • Insulin isophane-insulin regular • Insulin lispro • Insulin lispro-insulin lispro protamine	

	• Insulin glulisine • Insulin inhalation • Insulin isophane beef-pork		• Insulin regular human • Insulin zinc human		
Meglitinides	• Nateglinide		• Repaglinide		
Miscellaneous antidiabetic agents	• Exenatide	• Liraglutide	• Metformin-repaglinide	• Sitagliptin
Sulfonylureas	• Acetohexamide • Chlorpropamide	• Glimepiride • Glipizide	• Glyburide • Tolazamide	• Tolbutamide
Thiazolidinediones	• Pioglitazone		• Rosiglitazone		

2. Claims data –
   a. Patients who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting (Table 29.3), on different dates of service, with a diagnosis of diabetes. (Table 29.4)

   b. Patients who had one face-to-face encounter in an acute inpatient or ED setting (Table 29.3), with a diagnosis of diabetes (Table 29.4), during the measurement year or the year prior to the measurement year. Services may be counted over both years.

Table 29.3: Codes to Identify Visit Type

Description	CPT	UB Revenue
Outpatient	99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456	051x, 0520-0523, 0526-0529, 057x- 059x, 082x-085x, 088x, 0982, 0983
Nonacute inpatient	99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337	0118, 0128, 138, 0148, 0158, 019x, 0524, 0525, 055x, 066x
Acute inpatient	99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291	010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 0987
ED	99281-99285	045x, 0981

Table 29.4: Codes to Identify Diabetes

Description	ICD-9-CM Diagnosis
Diabetes	250, 3572, 3620, 36641, 6480

Exclusion(s):
   1. Diagnosis of active polycystic ovaries. (Table 29.5)
   2. Diagnosis of active gestational diabetes. (Table 29.5)
   3. Diagnosis of active steroid induced diabetes. (Table 29.5)

Table 29.5: Codes to Identify Required Exclusions

Description	ICD-9-CM Diagnosis
Gestational Diabetes	6488, 64880, 64881, 64882, 64883, 64884
Steroid induced diabetes	2518, 9620
Polycystic ovaries	2564

Result:
The result is expressed as a percentage.

Measure Qualifications:

The following link(s) may be used to obtain additional information regarding the original measure specification. This is provided without assurances.:

http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures.aspx

Measure Collection Description			
Setting of Care: **Multi-setting**		Reporting Period: **Annual; April**	
Experience Period: **Calendar Year**		Baseline Period: **CY 2013**	
Improvement Target Goal (ITG): **NA**		Absolute ITG Value: **NA**	
Attribution Date: **Last day of measurement period**		Anchor Date: **Last day of measurement period**	
Claim Type(s): **01, 03, 04, 12, 13, 14, 15, 16, 18**	**01** – Inpatient Hospital **02** – Long Term Care **03** – Outpatient Hospital **04** – Physician **05** – Chiropractor **06** – Home Health **07** – Transportation **08** – Vision	**09** – Supplies, DME **10** – Podiatry **11** – Dental **12** – Pharmacy **13** – EPDST/Healthstart **14** – Institutional Crossover **15** – Professional Crossover	**16** – Lab **17** – Prosthetic and Orthotics **18** – Independent Clinic **19** – Psychologists **21** – Optometrists **22** – Mid Level Practitioner **23** – Hearing Aid
Continuous Eligibility Period: **Yes**		Risk Adjustment: **No**	Sampling: **No**

Continuous Eligibility/ Risk Adjustment/ Sampling Methodology

The patient is to be continuously enrolled for the measurement year with no more than a 45 day gap during the year.

DSRIP Incentive Impact		
Project Title: Project 11 – Improve Overall Quality of Care for Patients Diagnosed with Diabetes Mellitus and Hypertension	Project Code: 11.4	Payment Method: Pay for Reporting
Project Title: Project 12 – Diabetes Group Visits for Patients and Community Education	Project Code: 12.4	Payment Method: Pay for Reporting
Universal Measure: No	Universal Code: NA	Payment Method: NA